BP‑1‑102 exerts antitumor effects on T‑cell acute lymphoblastic leukemia cells by suppressing the JAK2/STAT3/c‑Myc signaling pathway

Drug resistance and relapse of T-cell acute lymphoblastic leukemia (T-ALL) remain significant concerns for physicians; hence, the development and screening of effective targeted drugs remain important. Considering that STAT3 is emerging as a potential therapeutic target for T-ALL, T-ALL cell lines (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Can, Ruan, Xueqin, Zhao, Yan, Zhu, Hongkai, Wang, Canfei, Cheng, Zhao, Peng, Hongling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068411/
https://www.ncbi.nlm.nih.gov/pubmed/37020528
http://dx.doi.org/10.3892/etm.2023.11890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068411/
https://www.ncbi.nlm.nih.gov/pubmed/37020528
http://dx.doi.org/10.3892/etm.2023.11890

Ejemplares similares